| Literature DB >> 17126006 |
Abstract
Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause of maternal mortality. Conventional management is aimed at optimising uterine tone, replacing circulating volume and blood products, and surgery to achieve haemostasis. Recently there have been numerous reports of the (unlicensed) use of recombinant activated factor VII in the management of major obstetric haemorrhage. We report our experience of using it in the treatment of major post-partum haemorrhage in four previously healthy parturients. The published reports of recombinant activated factor VII use in post-partum haemorrhage (unrelated to pre-existing coagulopathies) are compared.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17126006 DOI: 10.1016/j.ijoa.2006.07.005
Source DB: PubMed Journal: Int J Obstet Anesth ISSN: 0959-289X Impact factor: 2.603